In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Effectiveness of cardiac rehabilitation in patients with type 2 diabetes mellitus after percutaneous coronary intervention.

Session The increasing evidence for cardiac rehabilitation

Speaker Maria Jose Romero Reyes

Event : ESC Congress 2015

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Rapid Fire Abstracts

Authors : M J Romero Reyes (Seville,ES), N Cobo Gomez (Seville,ES), P Escane Duarte (Seville,ES), R Picon Heras (Seville,ES), R Guerola Segura (Seville,ES), FJ Molano Casimiro (Seville,ES), L Pastor Torres (Seville,ES)

M.J. Romero Reyes1 , N. Cobo Gomez1 , P. Escane Duarte1 , R. Picon Heras1 , R. Guerola Segura1 , F.J. Molano Casimiro1 , L. Pastor Torres1 , 1University Hospital Virgen de Valme, Cardiology - Seville - Spain ,

European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 517

Introduction: Patients with diabetes mellitus are at increased risk of recurrent cardiovascular events after percutaneous coronary intervention.

Purpose: The aim of this study was to asses if cardiac rehabilitation decreases mortality and recurrence of cardiovascular events in this subgroup of patients after percutaneous coronary intervention.

Methods: We performed a retrospective cohort study of 318 consecutive patients with type 2 diabetes mellitus who underwent percutaneous coronary intervention in our hospital between September 2004 and January 2011. We classified the patients in two cohorts according to their participation (n=154) or not (n=164) in a cardiac rehabilitation programme. Events occurring in the first 2 years of follow-up were recorded.

Results: CR was associated with a significant decrease in all-cause mortality (OR 0,105 [95% CI: 0,31–0,356]; p<0,001) and cardiac mortality (OR 0,107 [95% IC: 0,24–0,468]; p<0,001) over a two year follow-up. No significant differences were observed in nonfatal myocardial infarction, stent restenosis and nonfatal stroke.

Conclusion: Participation in a CR programme after percutaneous coronary intervention is associated with a significant reduction in cardiac mortality and all-cause mortality rates in type 2 diabetic patients.

CR (n=154)No CR (n=164)P Value
Male sex133 (86%)100 (61%)0,000
Age (years)58±765±60,000
Hypertension113 (74%)111 (68%)0,228
Hypercholesterolemia112 (74%)115 (70%)0,423
Smoking102 (67%)75 (46%)0,000
Prior myocardial infarction24 (16%)32 (19%)0,372
Diastolic dysfunction (FE <50%)31 (22%)33 (23%)0,777
Multivessel disease79 (51%)116 (70%)0,000
Indication of revascularization:0,001
  Stable angina5 (3%)7 (4%)
  Unstable angina53 (35%)89 (56%)
  Myocardial infarction92 (60%)59 (37%)
  Cardiogenic shock2 (1%)4 (2%)
Incomplete revascularization80 (52%)81 (49%)0,648
Drug-eluting stent110 (79%)127 (80%)0,699
Stent diameter2,9±0,42,9±0,40,929
Stent length22±1124±140,265

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are